Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction
- PMID: 37962823
- DOI: 10.1007/s12265-023-10457-8
Slow-Reflow and Prognosis in Patients with High Parathyroid Hormone Levels Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction
Abstract
We aimed to evaluate the correlation among serum parathyroid hormone (PTH) and slow-reflow during primary percutaneous coronary intervention (PCI) and prognosis in patients with ST-segment elevation myocardial infarction (STEMI). A total of 262 patients were enrolled and divided into a slow-reflow group (n = 61) and a control group (n = 201). PTH was an independent risk factor for slow-reflow (P < 0.05), and the regression model had good discrimination and calibration. ROC curve analysis showed that PTH (≥ 63.65 pg/ml) had a predictive value for slow-reflow (P < 0.001). During the 1-year follow-up, the patients were divided into a PTH-h group (≥ 63.65 pg/ml, n = 100) and a PTH-l group (< 63.65 pg/ml, n = 162). Readmission for HF was independently associated with PTH levels (P < 0.05). KM survival analysis suggested that PTH-h had a predictive value for MACEs, especially for readmission for HF (P < 0.05). PTH levels were associated with slow-reflow during PCI and MACEs during follow-up in patients with STEMI.
Keywords: Acute ST-segment elevation myocardial infarction; Major adverse cardiovascular events; Parathyroid hormone; Percutaneous coronary intervention; Prognosis; Slow-reflow.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
The HALP score predicts no-reflow phenomenon and long-term prognosis in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.Coron Artery Dis. 2025 Jun 1;36(4):273-280. doi: 10.1097/MCA.0000000000001446. Epub 2024 Nov 4. Coron Artery Dis. 2025. PMID: 39492724 Free PMC article.
-
The relationship between atherogenic index of plasma and no-reflow in patients with acute ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention.Int J Cardiovasc Imaging. 2020 May;36(5):789-796. doi: 10.1007/s10554-019-01766-8. Epub 2020 Jan 9. Int J Cardiovasc Imaging. 2020. PMID: 31919706
-
Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Cardiol J. 2016;23(1):84-92. doi: 10.5603/CJ.a2015.0070. Epub 2015 Oct 27. Cardiol J. 2016. PMID: 26503078
-
Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.BMC Cardiovasc Disord. 2021 Oct 10;21(1):488. doi: 10.1186/s12872-021-02301-1. BMC Cardiovasc Disord. 2021. PMID: 34629058 Free PMC article.
-
Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis.BMC Cardiovasc Disord. 2018 May 2;18(1):75. doi: 10.1186/s12872-018-0812-6. BMC Cardiovasc Disord. 2018. PMID: 29716535 Free PMC article. Review.
References
-
- Gao G, Xu H, Zhang D, Song C, Guan C, Xu B, et al. The predictive value of baseline target lesion SYNTAX score for no-reflow during urgent percutaneous coronary intervention in acute myocardial infarction. J Interv Cardiol. 2021;2021:9987265. https://doi.org/10.1155/2021/9987265 . - DOI - PubMed - PMC
-
- Tasar O, Karabay AK, Oduncu V, Kirma C. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019;30(4):270–6. https://doi.org/10.1097/MCA.0000000000000726 . - DOI - PubMed
-
- Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18(1):3. https://doi.org/10.1186/s12872-017-0722-z . - DOI - PubMed - PMC
-
- Isaksson E, Almquist M, Seeberger A, Sterner G. Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients? Clin Exp Nephrol. 2018;22(5):1188–97. https://doi.org/10.1007/s10157-018-1543-9 . - DOI - PubMed - PMC
-
- Radhakrishnan A, Pickup LC, Price AM, Law JP, Edwards NC, Steeds RP, et al. Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy? Heart. 2019;105(17):1302–9. https://doi.org/10.1136/heartjnl-2019-315138 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous